Initial Experience with a Novel Desensitization Strategy for Carboplatin-associated Hypersensitivity Reactions: Carboplatin-hypersensitivity Reactions

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2003 Oct 18

PMID 14564516

Citations 6

Authors

Maurie Markman

Fred Hsieh

Kristine Zanotti

Kenneth Webster

Gertrude Peterson

Barbara Kulp

Ann Spicel

Jerome Belinson

Affiliations

Soon will be listed here.

Abstract

Purpose: Carboplatin hypersensitivity is an increasingly recognized toxicity in individuals receiving >6 cumulative courses of this important antineoplastic agent. We wished to determine if a novel multi-pronged approach to re-treating patients with a high risk for this potentially serious side effect could permit the safe delivery of this class of cytotoxic drugs.

Methods: Five patients with gynecologic malignancies who had either experienced a documented carboplatin hypersensitivity reaction ( n =4) or had a "positive" carboplatin skin test ( n =1), received a multi-drug oral regimen administered over several days which was designed to block known mediators of anaphylaxis. Four of these individuals subsequently underwent treatment with either cisplatin or carboplatin employing a "dose escalation" desensitization schema.

Results: Four patients underwent successful treatment with either cisplatin or carboplatin (3, 4, 5, 6+ total additional courses) without any further evidence of hypersensitivity.

Conclusion: In this preliminary report of a limited patient population, we have demonstrated the ability to safely deliver a platinum agent to individuals with either documented carboplatin hypersensitivity, or a high risk for this potentially serious toxicity of carboplatin. Further exploration of this novel management strategy in a larger group of patients is indicated.

Citing Articles

Platinum desensitization therapy and its impact on the prognosis of ovary high-grade serous adenocarcinoma: a real world-data.

Li K, Yin R Front Immunol. 2024; 15:1346464.

PMID: 38312839 PMC: 10834667. DOI: 10.3389/fimmu.2024.1346464.

Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin.

Kolomeyevskaya N, Lele S, Miller A, Riebandt G, Blum B, Odunsi K Int J Gynecol Cancer. 2014; 25(1):42-8.

PMID: 25356535 PMC: 5042199. DOI: 10.1097/IGC.0000000000000307.

Usefulness of desensitization protocol for a carboplatin hypersensitivity reaction during docetaxel-carboplatin therapy for recurrent ovarian cancer: Case report.

Shoji T, Takatori E, Kaido Y, Kumagai S, Takeuchi S, Yoshizaki A Oncol Lett. 2012; 1(6):1021-1023.

PMID: 22870105 PMC: 3412508. DOI: 10.3892/ol.2010.192.

Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.

Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif M Met Based Drugs. 2010; 2010.

PMID: 20886011 PMC: 2945654. DOI: 10.1155/2010/207084.

The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.

OCearbhaill R, Zhou Q, Iasonos A, Hensley M, Tew W, Aghajanian C Gynecol Oncol. 2009; 116(3):326-31.

PMID: 19944454 PMC: 4369374. DOI: 10.1016/j.ygyno.2009.10.070.

References

Chang S, Fryberger S, Crouse V, Tilford D, PRADOS M . Carboplatin hypersensitivity in children. A report of five patients with brain tumors. Cancer. 1995; 75(5):1171-5. DOI: 10.1002/1097-0142(19950301)75:5<1171::aid-cncr2820750518>3.0.co;2-f. View

Dizon D, Sabbatini P, Aghajanian C, Hensley M, Spriggs D . Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol. 2002; 84(3):378-82. DOI: 10.1006/gyno.2001.6519. View

Zanotti K, Rybicki L, Kennedy A, Belinson J, Webster K, Kulp B . Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol. 2001; 19(12):3126-9. DOI: 10.1200/JCO.2001.19.12.3126. View

Cromwell O, Pepys J, Parish W, Hughes E . Specific IgE antibodies to platinum salts in sensitized workers. Clin Allergy. 1979; 9(2):109-17. DOI: 10.1111/j.1365-2222.1979.tb01529.x. View

Broome C, Schiff R, Friedman H . Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Med Pediatr Oncol. 1996; 26(2):105-10. DOI: 10.1002/(SICI)1096-911X(199602)26:2<105::AID-MPO7>3.0.CO;2-P. View

Gore M, Fryatt I, Wiltshaw E, Dawson T . Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 1990; 36(2):207-11. DOI: 10.1016/0090-8258(90)90174-j. View

GOLDBERG A, Confino-Cohen R, Fishman A, Beyth Y, Altaras M . A modified, prolonged desensitization protocol in carboplatin allergy. J Allergy Clin Immunol. 1996; 98(4):841-3. DOI: 10.1016/s0091-6749(96)70134-3. View

Robinson J, Singh D, Wharton J, Gershenson D, Wolf J . Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol. 2001; 82(3):550-8. DOI: 10.1006/gyno.2001.6331. View

Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J . Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol. 2000; 18(1):102-5. DOI: 10.1200/JCO.2000.18.1.102. View

10.

Morgan J, Adams M, Mason M . Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer. 1994; 30A(8):1205-6. DOI: 10.1016/0959-8049(94)90489-8. View

11.

Orbaek P . Allergy to the complex salts of platinum. A review of the literature and three case reports. Scand J Work Environ Health. 1982; 8(2):141-5. View

12.

Weidmann B, Mulleneisen N, Bojko P, Niederle N . Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management. Cancer. 1994; 73(8):2218-22. DOI: 10.1002/1097-0142(19940415)73:8<2218::aid-cncr2820730830>3.0.co;2-1. View

13.

Zanotti K, Markman M . Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf. 2001; 24(10):767-79. DOI: 10.2165/00002018-200124100-00005. View

14.

Markman M, Bookman M . Second-line treatment of ovarian cancer. Oncologist. 2000; 5(1):26-35. DOI: 10.1634/theoncologist.5-1-26. View

15.

Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J . Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens. Gynecol Oncol. 1997; 65(3):434-6. DOI: 10.1006/gyno.1997.4708. View

16.

Gershenson D, Kavanagh J, Copeland L, Stringer C, Morris M, Wharton J . Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy. Obstet Gynecol. 1989; 73(5 Pt 1):798-802. View

17.

Zweizig S, Roman L, Muderspach L . Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol. 1994; 53(1):121-2. DOI: 10.1006/gyno.1994.1098. View

18.

Essayan D, Colarusso P, Lichtenstein L, Ozols R, King E . Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol. 1996; 97(1 Pt 1):42-6. DOI: 10.1016/s0091-6749(96)70281-6. View

19.

Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B . Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999; 17(4):1141. DOI: 10.1200/JCO.1999.17.4.1141. View

20.

Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S . Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991; 9(3):389-93. DOI: 10.1200/JCO.1991.9.3.389. View